Your browser doesn't support javascript.
loading
COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.
Zafar, Saman; Arshad, Muhammad Sohail; Fatima, Sameen; Ali, Amna; Zaman, Aliyah; Sayed, Elshaimaa; Chang, Ming-Wei; Ahmad, Zeeshan.
Afiliação
  • Zafar S; Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Arshad MS; Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Fatima S; Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Ali A; Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
  • Zaman A; Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
  • Sayed E; Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
  • Chang MW; Nanotechnology and Integrated Bioengineering Centre, University of Ulster, Northern Ireland BT37 0QB, UK.
  • Ahmad Z; Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.
Pharmaceutics ; 12(10)2020 Oct 03.
Article em En | MEDLINE | ID: mdl-33023033
ABSTRACT
SARS-CoV-2 has affected people from all age groups, races and ethnicities. Given that many infected individuals are asymptomatic, they transmit the disease to others unknowingly, which has resulted in the spread of infection at an alarming rate. This review aims to provide an overview of the pathophysiology, preventive measures to reduce the disease spread, therapies currently in use, an update on vaccine development and opportunities for vaccine delivery. The World Health Organization has advised several precautions including social distancing, hand washing and the use of PPE including gloves and face masks for minimizing the spread of SARS-CoV-2 infection. At present, several antiviral therapies previously approved for other infections are being repositioned to study their efficacy against SARS-CoV-2. In addition, some medicines (i.e., remdesivir, chloroquine, hydroxychloroquine) have received emergency use authorisation from the FDA. Plasma therapy has also been authorised for emergency use for the treatment of COVID-19 on a smaller scale. However, no vaccine has been approved so far against this virus. Nevertheless, several potential vaccine targets have been reported, and development of different types of vaccines including DNA, mRNA, viral vector, inactivated, subunit and vaccine-like particles is in process. It is concluded that a suitable candidate delivered through an advanced drug delivery approach would effectively boost the immune system against this coronavirus.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Paquistão

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Paquistão